Scarica l'app Stockscreener
9.98
2.15%
0.21
Precedente Chiudi:
$9.77
Aprire:
$9.89
Volume 24 ore:
11,947
Relative Volume:
0.04
Capitalizzazione di mercato:
$568.50M
Reddito:
-
Utile/perdita netta:
$-66.86M
Rapporto P/E:
-8.3167
EPS:
-1.2
Flusso di cassa netto:
$-58.82M
1 W Prestazione:
+6.29%
1M Prestazione:
+52.37%
6M Prestazione:
+149.50%
1 anno Prestazione:
+61.49%
Intervallo 1D:
$9.69
$9.98
Intervallo di 1 settimana:
$8.58
$10.02
Portata 52W:
$2.60
$10.02
Design Therapeutics Inc Stock (DSGN) Company Profile
Nome
Design Therapeutics Inc
Settore
Industria
Telefono
858-293-4900
Indirizzo
6005 HIDDEN VALLEY ROAD, CARLSBAD
Confronta DSGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
9.98 | 559.38M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.80 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.19 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.67 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.52 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.57 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Iniziato | Craig Hallum | Buy |
| 2025-12-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-05-04 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-06-10 | Iniziato | Wedbush | Outperform |
| 2022-05-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-01-19 | Iniziato | Goldman | Sell |
| 2021-04-20 | Iniziato | Goldman | Neutral |
| 2021-04-20 | Iniziato | Piper Sandler | Overweight |
| 2021-04-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Design Therapeutics Inc Borsa (DSGN) Ultime notizie
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Raised to "Strong-Buy" at Craig Hallum - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Rating Upgraded by Leerink Partnrs - Defense World
Why retail investors pile into Design Therapeutics Inc. stock2025 Technical Overview & Weekly High Return Stock Forecasts - Newser
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat
Leerink Partnrs Upgrades Design Therapeutics (NASDAQ:DSGN) to "Strong-Buy" - MarketBeat
How Design Therapeutics Inc. stock reacts to Fed rate cuts2025 Bull vs Bear & Smart Money Movement Tracker - Newser
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress - Investing.com Nigeria
Leerink Partners Upgrades Design Therapeutics (DSGN) - Nasdaq
Design Therapeutics Shares Rise After Leerink Upgrade - marketscreener.com
Design Therapeutics, Inc. (DSGN): Analysts Upgrade to Outperform Amid Positive Price Potential - Stocks Telegraph
Craig-Hallum initiates Design Therapeutics stock with Buy rating By Investing.com - Investing.com Australia
Craig-Hallum initiates Design Therapeutics stock with Buy rating - Investing.com
Leerink Upgrades Design Therapeutics to Outperform From Market Perform, Adjusts PT to $14 From $7 - MarketScreener
Will Design Therapeutics Inc. stock deliver shareholder valueWeekly Trend Summary & Risk Managed Investment Strategies - Newser
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer - Yahoo Finance
How Design Therapeutics Inc. stock performs in weak economyNew Guidance & Safe Entry Point Alerts - Newser
Trevi Therapeutics Inc Strengthens Strategy For Clinical Design - Kalkine Media
Will Aries Agro Limited Stock Benefit From Industry Trends in YEARSupport Level Holds & Free Double Digit Growth Tips - earlytimes.in
Why Design Therapeutics Inc. stock is rated strong buyWeekly Market Report & Consistent Income Trade Recommendations - BỘ NỘI VỤ
Design Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Design Therapeutics (Nasdaq: DSGN) to Participate in Piper Sandler and Evercore 2025 Events - Stock Titan
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth - simplywall.st
Design Therapeutics upgraded to Outperform from Sector Perform at RBC Capital - MSN
Design Therapeutics spikes as RBC upgrades on an eventful 2026 - MSN
RBC Capital Upgrades Design Therapeutics (DSGN) - Nasdaq
Design Therapeutics, Inc.Common Stock (Nasdaq:DSGN) Stock Quote - Markets Financial Content
Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says - MarketScreener
Design Therapeutics stock up as RBC upgrades (DSGN:NASDAQ) - Seeking Alpha
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday - Benzinga
Design Therapeutics : DSGN - 24/7 Wall St.
Design Therapeutics stock rating upgraded by RBC Capital on improved outlook - Investing.com Nigeria
RBC Upgrades Design Therapeutics to Outperform From Sector Perform, Boosts Price Target to $13 From $6, Keeps Speculative Risk - MarketScreener
Can Design Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Breakouts & Safe Entry Point Identification - newser.com
Fuchs Dystrophy Clinical Trial Assessment 2025: Over 5 Global - openPR.com
Why retail investors favor Design Therapeutics Inc. stockJuly 2025 Closing Moves & Target Return Focused Stock Picks - newser.com
Is Design Therapeutics Inc. stock poised for growthTrade Analysis Summary & Safe Swing Trade Setups - newser.com
How to interpret RSI for Design Therapeutics Inc. stock2025 Price Momentum & Fast Gain Stock Trading Tips - newser.com
Can Design Therapeutics Inc. stock sustain institutional interest - newser.com
Analyzing Design Therapeutics Inc. with risk reward ratio chartsJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Technical signs of recovery in Design Therapeutics Inc.Weekly Stock Summary & Technical Buy Zone Confirmations - newser.com
Shareholder Logos Global Master Fund LP Files To Sell 120,000 Of Design Therapeutics Inc [DSGN] - TradingView
Published on: 2025-11-17 12:13:42 - newser.com
Is Design Therapeutics Inc. forming a bottoming baseMarket Sentiment Report & AI Forecast for Swing Trade Picks - newser.com
Design Therapeutics (DSGN) Price Target Increased by 13.64% to 8.50 - Nasdaq
How high can Design Therapeutics Inc. stock goJuly 2025 Momentum & Low Drawdown Momentum Ideas - newser.com
Regression analysis insights on Design Therapeutics Inc. performanceJuly 2025 Patterns & Community Consensus Trade Alerts - newser.com
Should you wait for a breakout in Design Therapeutics Inc.Weekly Gains Summary & Free Technical Pattern Based Buy Signals - newser.com
Developing predictive dashboards with Design Therapeutics Inc. dataJuly 2025 Volume & Fast Gaining Stock Reports - newser.com
How to integrate Design Therapeutics Inc. into portfolio analysis toolsDividend Hike & Accurate Entry/Exit Alerts - newser.com
Design Therapeutics Inc Azioni (DSGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.03%
0.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):